Nordisk – Page 2

Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

3 months ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, Incretins, Leadership Change, Market, Maziar Mike Doustdar, Nordisk, Obesity, Ozempic, pipeline, Wegovy

Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change

Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift

3 months ago talkbio0Tagged competition, GLP-1/GIP co-agonist, Leadership Change, Market, Nordisk, Obesity, pipeline cull, R&D pipeline, semaglutide, strategic shift, Wegovy

Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition

Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

3 months ago talkbio0Tagged CEO, competition, Drops - Drug Form, drug market, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Prices, Regulatory Affairs, Shakeup, SmithKline Beecham, United States Food and Drug Administration

Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA

Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance

3 months ago talkbio0Tagged CEO, Changing, drug competition, growth outlook, guidance cut, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Sales - occupational activity, Transition Mutation

Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition

Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges

3 months ago talkbio0Tagged Appointments, CEO, Drug Industry, drug market, growth outlook, international operations, Leadership Change, Maziar Mike Doustdar, Nordisk, Obesity

Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

4 months ago talkbio0Tagged deceptive marketing, Glucagon-Like Peptide 1, Hims & Hers, Nordisk, partnership termination, stock plunge, Telemedicine, Wegovy, Weight-Loss Agents

Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

4 months ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

4 months ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

5 months ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs

5 months ago talkbio0Tagged cardiometabolic disease, Deep Apple, Drug Discovery, G-Protein-Coupled Receptors, Non-Incretin, Nordisk, Obesity, research collaboration, Small Molecule

Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery